This material identity review provides structural, chemical, and analytical characterization data for synthetic cagrilintide peptide material utilized in controlled laboratory settings. As a long-acting acylated amylin analog, cagrilintide serves as a primary tool for investigating amylin receptor signaling, gastric emptying kinetics, and energy homeostasis in preclinical models. This document outlines analytical verification standards, structural parameters, and handling protocols for research personnel.
This material identity review provides structural, chemical, and analytical characterization data for synthetic cagrilintide peptide material utilized in controlled laboratory settings. As a long-acting acylated amylin analog, cagrilintide serves as a primary tool for investigating amylin receptor signaling, gastric emptying kinetics, and energy homeostasis in preclinical models. This document outlines analytical verification standards, structural parameters, and handling protocols for research personnel.
A cagrilintide synthetic peptide material identity review establishes the verified chemical structure, primary sequence, molecular mass, and analytical purity of cagrilintide for laboratory research use. Cagrilintide is a long-acting, acylated non-selective amylin receptor agonist designed for in vitro signaling assays and animal metabolic research models, requiring identity confirmation via mass spectrometry and RP-HPLC.
Analytical validation ensures that the synthetic sequence corresponds precisely to reference standards without truncations or unidentified side-products. Laboratories utilizing cagrilintide research material rely on lot-specific documentation to confirm structural integrity, net peptide content, and the absence of residual synthesis reagents prior to protocol execution.
Cagrilintide is a synthetic analog of human amylin (islet amyloid polypeptide, or IAPP). Structural modification of native amylin is necessary for laboratory research due to the native peptide's rapid enzymatic degradation and propensity to form insoluble beta-sheet amyloid fibrils in aqueous solution. Cagrilintide addresses these biophysical challenges through strategic amino acid substitutions and hydrophobic side-chain modification.
The primary sequence of cagrilintide incorporates an acylation motif—specifically a C18 fatty diacid chain attached via a lipophilic gamma-glutamyl spacer to a lysine residue. This acylation enables non-covalent binding to serum albumin in animal models, significantly extending its biological half-life in vivo relative to un-acylated amylin receptor agonists. Furthermore, structural substitutions within the peptide core prevent self-aggregation into amyloid plaque, maintaining stable monomeric conformations in reconstitution buffers across extended experimental timeframes.
The molecular formula of cagrilintide reflects a high-molecular-weight acylated peptide, with a theoretical monoisotopic mass that must be confirmed by high-resolution liquid chromatography-mass spectrometry (LC-MS). Identity testing must demonstrate both the correct peptide backbone sequence and the precise site-specific attachment of the fatty acid moiety.
In preclinical pharmacodynamics, cagrilintide functions as a non-selective agonist at human and rodent amylin receptors (AMYR1, AMYR2, and AMYR3), which are GPCR complexes consisting of the calcitonin receptor (CTR) core co-expressed with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). In vitro receptor-binding assays indicate that cagrilintide displays nanomolar affinity across all three RAMP-CTR combinations, activating intracellular cyclic AMP (cAMP) accumulation pathways with high potency.
Additionally, cagrilintide exhibits potent agonist activity directly at the calcitonin receptor itself, independent of RAMP co-expression. This dual AMYR/CTR activation profile differentiates cagrilintide from selective single-receptor ligands. In cell-based reporter assays, cagrilintide engagement of AMYR complexes initiates downstream signal transduction via $G_{\alpha s}$-mediated adenylate cyclase activation, leading to protein kinase A (PKA) phosphorylation and modulation of downstream transcription factors involved in metabolic regulation.
Preclinical studies suggest that cagrilintide binding to central amylin receptors located in the area postrema and nucleus of the solitary tract (NST) triggers neurosignaling cascades that suppress food intake and delay gastric emptying in rodent paradigms. The molecular identity of the compound directly dictates these receptor-binding kinetics, making verification of sequence purity essential for reproducible in vitro data.
The preclinical literature regarding cagrilintide centers primarily on rodent models of diet-induced obesity (DIO), knockout mouse lines, and isolated tissue culture systems evaluating gastric motility. Research models utilize cagrilintide to investigate the central nervous system mechanisms underlying satiety signaling, hindbrain signal integration, and energy expenditure.
In animal studies, administration of acylated amylin analogs like cagrilintide results in a sustained, dose-dependent reduction in cumulative food intake without inducing conditional taste aversion at physiological target concentrations. In vitro gastric tissue strip assays demonstrate that cagrilintide attenuates smooth muscle contraction frequency, confirming its involvement in regulating gastrointestinal transit rates.
Furthermore, researchers explore cagrilintide within multi-hormonal co-formulation research. In preclinical trial settings, combining amylin receptor agonists with incretin mimetics produces additive or synergistic reductions in body mass and improvements in glycemic parameters compared to monotherapies. To access relevant research compounds for such co-administration studies, investigators consult the PX1 Research catalog of research peptides.
To properly contextualize cagrilintide within metabolic research, investigators evaluate its physical and pharmacological properties against other synthetic peptidergic compounds used in energy-balance models. While incretin mimetics target the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, amylin analogs operate through distinct calcitonin-receptor complexes.
In comparative preclinical assays, cagrilintide is evaluated alongside the mono-incretin agonist semaglutide, the dual GIP/GLP-1 receptor agonist tirzepatide, and the first-generation unacylated amylin analog pramlintide structural assays. While pramlintide exhibits a short pharmacokinetic half-life requiring frequent administration in animal models, cagrilintide’s C18 diacid acylation confers prolonged plasma retention. Unlike semaglutide and tirzepatide, which act principally via incretin pathways in the hypothalamus and pancreas, cagrilintide targets area postrema AMYR complexes, providing a distinct neuroendocrine target profile that researchers combine in dual-pathway metabolic paradigms.
Establishing material identity for synthetic cagrilintide requires a rigorous suite of analytical techniques. Because synthetic peptide manufacturing involves step-wise solid-phase peptide synthesis (SPPS), potential impurities include deletion sequences, racemized amino acid derivatives, incomplete deprotection artifacts, and free fatty acid reagents.
High-Performance Liquid Chromatography (RP-HPLC) with reverse-phase C18 or C8 columns is the standard method for evaluating chromatographic purity. A acceptable material standard for laboratory research requires a main peak area of $\ge 98.0\%$ at UV wavelengths of 214 nm and 280 nm. Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) is simultaneously employed to confirm exact molecular weight within $\pm 1.0\text{ Da}$ of theoretical mass.
Beyond chromatographic purity, the determination of net peptide content (NTA or amino acid analysis) is critical. Lyophilized peptide cakes contain counterions (typically trifluoroacetate, TFA) and residual moisture. Quantitative NMR or elemental analysis establishes the exact percentage of active peptide mass within a given vial, allowing investigators to calculate precise molar concentrations for quantitative in vitro binding studies.
In cell culture assays and in vivo animal research, bacterial endotoxin contamination represents a major confounding variable. Endotoxins (lipopolysaccharides, LPS) trigger Toll-like receptor 4 (TLR4) inflammatory cascades, inducing fever, cytokine release, and altered metabolic states that invalidate experimental outcomes.
PX1 Research subjects every lot of cagrilintide to quantitative Limulus Amebocyte Lysate (LAL) or recombinant Factor C (rFC) endotoxin testing in accordance with USP <85> guidelines. Research material must register endotoxin levels well below strict limits (typically $< 0.05\text{ EU/mg}$) to ensure suitability for sensitive primary neuronal cultures and parenteral animal dosing models.
All material is processed within cGMP-compliant facilities using ISO 17025 certified analytical laboratories. Comprehensive documentation detailing purity, mass spectra, and endotoxin metrics is published in a lot-specific Certificate of Analysis (COA) accompanying each shipment.
Synthesized cagrilintide is supplied as a sterile, lyophilized cake designed exclusively for laboratory research use. Proper handling protocols are required to preserve peptide stability and prevent physical aggregation.
Lyophilized cagrilintide should be stored at $-20^\circ\text{C}$ to $-80^\circ\text{C}$ upon receipt, protected from light and moisture. Prior to opening, vials should be allowed to equilibrate to room temperature to prevent condensation from introducing moisture into the desiccated powder.
Reconstitution should be performed using sterile research-grade diluents such as Bacteriostatic Water, sterile normal saline ($0.9\%\text{ NaCl}$), or dilute acetic acid/phosphate buffer systems tailored to the target pH of the experimental assay. Due to the acylated hydrophobic tail, initial wetting with a minor volume of neutral or slightly alkaline buffer (pH 7.4–8.0) may facilitate rapid dissolution without vigorous vortexing, which can induce mechanical shear and aggregate formation. Reconstituted aliquots should be frozen at $-80^\circ\text{C}$ for long-term storage, avoiding repeated freeze-thaw cycles.
Reliable experimental outcomes depend entirely on the purity and consistency of starting chemical materials. PX1 Research provides USA-manufactured research peptides synthesized under stringent quality control frameworks.
Every batch of synthetic cagrilintide undergoes independent third-party HPLC and MS testing to confirm material identity and purity. Researchers evaluating compound suppliers can inspect our complete protocol data via the PX1 research portal.
PX1 Research operates dedicated fulfillment centers in California and Arizona, providing same-day shipping for orders placed before standard cutoff times (Monday through Friday). Principal investigators and laboratory managers interested in bulk procurement or institutional accounts are encouraged to explore our bulk laboratory accounts program for dedicated account support and lot-reservation services.
What is the primary molecular target of cagrilintide in research models?
Cagrilintide acts as a non-selective agonist at amylin receptors (AMYR1, AMYR2, AMYR3) and calcitonin receptors (CTR), inducing intracellular cAMP accumulation in target cell populations.
How does acylation alter the physical properties of cagrilintide compared to native amylin?
The attachment of a C18 fatty diacid chain increases hydrophobic binding to serum albumin, extending circulation half-life in vivo and reducing rapid renal clearance without compromising receptor activation affinity.
What analytical methods are required to verify cagrilintide material identity?
Material identity verification requires reverse-phase high-performance liquid chromatography (RP-HPLC) to assess purity and mass spectrometry (ESI-MS or MALDI-TOF) to confirm theoretical molecular mass.
What is the acceptable endotoxin threshold for cagrilintide used in preclinical research?
PX1 Research enforces endotoxin thresholds below 0.05 EU/mg via USP <85> LAL testing to prevent unwanted inflammatory responses in cell cultures and animal models.
How should lyophilized cagrilintide be stored upon arrival at the laboratory?
Lyophilized cagrilintide should be stored at -20°C to -80°C in a desiccated environment protected from light. Desiccation prevents premature hydrolysis before reconstitution.
What buffer conditions are recommended for reconstituting cagrilintide?
Reconstitution in sterile bacteriostatic water or neutral phosphate-buffered saline (pH 7.4) is typical. Gentle agitation without high-shear vortexing is recommended to maintain monomeric stability.
Does PX1 Research provide lot-specific COAs for cagrilintide?
Yes. Every lot of cagrilintide shipped by PX1 Research includes a third-party Certificate of Analysis detailing RP-HPLC purity profiles, mass spectrometry verification, net peptide content, and endotoxin levels.
Is cagrilintide approved for human clinical use or patient therapy?
No. Cagrilintide provided by PX1 Research is a synthetic research peptide intended strictly for laboratory and preclinical research use. It is not for human, veterinary, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.